Sessions

The BIO CEO & Investor Conference program features issue-oriented business, policy, and therapeutic discussions.

Past speakers include MDs, CSOs and industry analysts discussing the latest information on pipeline innovation along with industry executives and analysts who delve into timely and relevant business models, deal-making, and investment trends.

AI within Biopharma: Separating Value from Hype

Brain Health Discoveries: Neuropsychiatric Progress and New Cellular Maps

Market Outlook: Assessing Readiness for the Next IPO Window

Opportunities for Financing Your Company

Policy Outlook: Understanding Pricing and Access for Medicines

Recognizing the Patterns in Strategic M&A during Down Markets

Tackling Challenges in Oncology Drug Discovery

And more - check back soon for sessions and speakers.

It's the kind of meeting where biotech newsmakers can have productive dialogs with investors and other key players.

Luke Timmerman
The Timmerman Report
It's the caliber of attendees - biopharma companies on the verge of their next big step and investors looking for smart opportunities - that make BIO CEO & Investor Conference vital to the industry.

Anna Kazanchyan, M.D.
CEO & Chairwoman, Saghmos Therapeutics
The BIO CEO & Investor Conference offers a collaborative forum where executives, investors and industry stakeholders can come together to learn and exchange ideas about innovation in the biopharma ecosystem.

Phillip Ross
Global Chairman J.P. Morgan Healthcase Investment Banking
The BIO CEO & Investor Conference provides timely and relevant content on the issues driving the business of biotech, along with an invaluable platform for networking and partnering.

Chris Garabedian
CEO, Xontogency and Portfolio Manager, PXV Fund

Program

Session topics include: